

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **May 9, 2023**

---

**TREVENA, INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**

(State or other jurisdiction of incorporation)

**001-36193**  
(Commission  
File No.)

**26-1469215**  
(IRS Employer  
Identification No.)

---

**955 Chesterbrook Boulevard, Suite 110  
Chesterbrook, PA 19087**  
(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(610) 354-8840**

**Not applicable**

(Former name or former address, if changed since last report.)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered</u>
Common Stock, \$0.001 par value	TRVN	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 2.02. Results of Operations and Financial Condition.**

On May 9, 2023, Trevena, Inc. (the “Company”) stated that it expects to announce its operating results for the quarter ended as of March 31, 2023 on May 15, 2023 (the “First Quarter Results”). As part of the First Quarter Results, the Company expects an updated and extended cash runway, with a preliminary estimate of cash, cash equivalents, and marketable securities of approximately \$27.4 million as of March 31, 2023 (the “First Quarter Cash”), which the Company believes will be sufficient to fund the Company’s operations through year-end 2023.

With the Company’s recent announcement that its partner in China, Jiangsu Nhwa Pharmaceutical Co., Ltd., received formal approval from the National Medical Products Administration for OLINVYK, the Company is due to receive a \$3 million milestone payment and also is eligible to receive \$15 million upon first commercial sale of OLINVYK in China, in connection with its non-dilutive royalty-based financing with an affiliate of R-Bridge Healthcare Fund. These funds, together with the First Quarter Cash, are expected to extend the Company’s cash runway until mid-2024. The Company also expects to report approximately \$6,000 of net revenue for the period ending March 31, 2023.

The information above related to the Company’s expected operating results for the quarter ended as of March 31, 2023, including revenue and cash, cash equivalents and marketable securities is preliminary, has not been audited and is subject to change upon completion of the audit of the Company’s financial statements as of, and for the year ended, December 31, 2023.

The information under this caption is furnished by the Company in accordance with Securities Exchange Commission Release No. 33-8216. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date of this Current Report, except as shall be expressly set forth by specific reference in such a filing.

**Item 8.01 Other Events.**

On May 9, 2023, the Company issued a press release announcing that it will release its first quarter 2023 financial results on May 15, 2023. Details for the earnings call are contained in the press release. A copy of the press release is furnished hereto as Exhibit 99.1 and incorporated herein by reference.

The information set forth in this Item 8.01 and furnished hereto as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**(d) Exhibits

<b>Number</b>	<b>Description</b>
<u>99.1</u>	<u>Press Release dated May 9, 2023</u>
104	The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**TREVENA, INC.**

Date: May 9, 2023

By: /s/ Barry Shin  
Barry Shin  
Senior Vice President & Chief Financial Officer

---

**Trevena to Release First Quarter 2023 Financial Results on May 15, 2023**

--

***Company to host a Conference Call & Webcast at 8:00 a.m. ET***

CHESTERBROOK, Pa., May 9, 2023 -- **Trevena, Inc. (Nasdaq: TRVN)**, a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the first quarter ended March 31, 2023, prior to the market open on Monday, May 15, 2023.

The Company will host a conference call and webcast with the investment community at 8:00 a.m. ET that same day, featuring remarks by Carrie Bourdow, President and Chief Executive Officer, Patricia Drake, SVP and Chief Commercial Officer, Mark Demitrack, M.D., SVP and Chief Medical Officer, and Barry Shin, SVP and Chief Financial Officer.

<b>Title:</b>	Trevena First Quarter 2023 Financial Results Conference Call & Webcast
<b>Date:</b>	Monday, May 15, 2023
<b>Time:</b>	8:00 a.m. ET
<b>Conference Call Details:</b>	Toll-Free: 1-844-825-9789 International: 1-412-317-5180 Conference ID: 10178141

The conference call will be webcast live from the Company's website and will be available via the following links:

[https://viaavid.webcasts.com/starthere.jsp?ei=1610714&tp\\_key=d4c27074df](https://viaavid.webcasts.com/starthere.jsp?ei=1610714&tp_key=d4c27074df)

**Webcast:**

<https://www.trevena.com/investors/events-presentations/ir-calendar>

The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company's website.

**About Trevena**

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK<sup>®</sup> (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company's novel pipeline is based on Nobel Prize winning research and includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder.

For more information, please visit [www.Trevena.com](http://www.Trevena.com)

---

**For more information, please contact:**

**Investor Contact:**

Dan Ferry - Managing Director  
LifeSci Advisors, LLC  
daniel@lifesciadvisors.com  
(617) 430-7576

**Company Contact:**

Bob Yoder  
SVP and Chief Business Officer  
Trevena, Inc.  
(610) 354-8840

---